INFLUENCE OF NEUROTROPHIC FACTORS ON THE RISK OF DEVELOPING COGNITIVE DISORDERS IN PARKINSON'S DISEASE
Keywords:
dementia, Parkinson's disease, MMP-9, NGF, IL-1, IL-6Abstract
The article presents data on the analysis of neurotrophic factors and their influence on the risk of developing cognitive impairment and dementia in patients with Parkinson's disease. A comparative assessment of Matrix metalloproteinase-9 and nerve growth factor and interleukin profile is given, and the prognostic value of their inclusion in diagnostic algorithms is assessed.
References
Aarsland D., Beyer M.K., Kurz M.W. Dementia in Parkinson's disease. Curr. Opin. Neurol. 2018;21(6):676–682.
Svenningsson P., Westman E., Ballard C., Aarsland D. Cognitive impairment in patients with Parkinson's disease. Lancet Neurol. 2015;11(8):697–707.
Chahine L.M., Xie S.X., Simuni T. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behaviour disorder. Parkinsonism Relat Disord. 2016;27:102–106.
Zhang W., Wang T., Pei Z. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2015;19(6):533–542.
Bruno M.A., Cuello A.C. Activity-dependent release of precursor nerve growth factor and its maturation in CNS. Proc. Natl. Acad. Sci. USA. 2016;103(17):6735–6740.
Coughlin D.G., Hurtig H.I., Irwin D.J. Pathological influences on clinical heterogeneity in Lewy body diseases. Mov. Disord. 2020;35(1):5– 19.
Khaydarova D.K., Mansurova N.A. Analysis of Motor Complications in Parkinson’s Disease Phenotypes. Journal of Advances in Medicine and Medical Research. 25(5): 1-7, 2018;
Hansson O., Hall S., Ohrfelt A., et al. Levels of CSF α-synuclein oligomers in Parkinson's disease dementia. Alzheimers Res Ther. 2014;6(3):25.
Cheng B., Mattson M.P. NGF protects neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron. 2021;7(6):1031– 1041.
